Trazodone Safety in Older Adults (50 to 64): Risks, Dosing, and What Your Doctor Should Monitor

Why Trazodone Use Peaks in the 50-to-64 Age Group

Sleep complaints surge during the fifth and sixth decades of life, driven by hormonal shifts, rising rates of chronic pain, and accumulating cardiovascular disease burden. Trazodone has become one of the top three medications prescribed off-label for insomnia in the United States. A 2014 cross-sectional analysis using IMS Health data found that trazodone accounted for approximately 5.4 million prescriptions annually for insomnia, second only to zolpidem 1.

The appeal is straightforward: trazodone is inexpensive as a generic, carries no DEA scheduling, and does not produce the dependence profile associated with benzodiazepines or Z-drugs. Mendelson's 2005 review in the Journal of Clinical Psychiatry noted that trazodone was the most frequently prescribed agent for insomnia in the U.S. despite limited randomized controlled trial support for that indication 2. That paradox persists. Clinicians prescribe it because the alternative sleep medications present their own risks in this age bracket, including next-day cognitive impairment with zolpidem and rebound insomnia with benzodiazepines.

For adults between 50 and 64, the calculus shifts. Hepatic metabolism slows. Cardiovascular comorbidities accumulate. The medication list grows. Each of these changes alters trazodone's risk-benefit ratio in ways that warrant careful, individualized evaluation before the first dose.

Orthostatic Hypotension: The Most Common Safety Concern

Orthostatic hypotension is the single most clinically relevant adverse effect of trazodone in adults aged 50 to 64. Trazodone blocks alpha-1 adrenergic receptors, which reduces peripheral vascular resistance and can cause blood pressure to drop sharply upon standing. The FDA-approved labeling reports that orthostatic hypotension occurred in clinical trials at rates requiring dose adjustment or discontinuation in a subset of patients 3.

This matters more after 50. Baroreceptor sensitivity declines with age. Arterial stiffness increases. Adults in this group are also more likely to be taking antihypertensives, diuretics, or alpha-blockers for benign prostatic hyperplasia, all of which compound the hypotensive effect. A 2011 study published in the Journal of the American Geriatrics Society found that the use of trazodone was associated with a significantly increased risk of falls in community-dwelling older adults (adjusted OR 1.60, 95% CI 1.18 to 2.16) 4.

Practical risk reduction requires three steps. First, start at 25 mg, not 50 mg, especially if the patient takes any blood-pressure-lowering medication. Second, instruct patients to sit on the edge of the bed for 30 seconds before standing after their first dose. Third, check standing blood pressure at the one-week follow-up visit.

Cardiac Risks: QT Prolongation and Arrhythmia

Trazodone carries dose-dependent effects on cardiac repolarization. The drug blocks the hERG potassium channel, and post-marketing reports have documented cases of QT prolongation, torsades de pointes, and ventricular tachycardia 3. These events cluster at higher antidepressant doses (above 300 mg per day), but the 50-to-64 age group may be vulnerable even at moderate doses due to pre-existing cardiac substrate.

The American Heart Association's 2010 scientific statement on drug-induced QT prolongation noted that risk factors include female sex, hypokalemia, hypomagnesemia, structural heart disease, and concurrent use of other QT-prolonging drugs 5. Adults aged 50 to 64 are statistically more likely to have at least one of these risk factors than younger patients.

A baseline ECG before starting trazodone is reasonable clinical practice for this age group. The 2023 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias supports ECG monitoring when initiating QT-prolonging medications in patients with cardiac risk factors 6. If the corrected QT interval exceeds 470 ms in women or 450 ms in men, an alternative sleep agent should be considered.

Drug Interactions and Polypharmacy in the 50-to-64 Bracket

Polypharmacy defines this age group. The CDC's National Health and Nutrition Examination Survey data show that 39% of adults aged 40 to 59 use three or more prescription drugs, and that percentage climbs past 50 by age 60 7. Trazodone is metabolized primarily by hepatic CYP3A4, with a secondary contribution from CYP2D6. Any drug that inhibits CYP3A4 can raise trazodone plasma concentrations substantially.

The FDA label warns specifically that concurrent use of CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin) may necessitate a trazodone dose reduction 3. A pharmacokinetic study demonstrated that ritonavir increased trazodone AUC by more than 2-fold, leading to increased adverse effects including nausea, hypotension, and syncope 8.

Three interaction categories demand attention:

Serotonergic combinations. Trazodone combined with SSRIs, SNRIs, tramadol, or triptans raises serotonin syndrome risk. The FDA issued a 2016 Drug Safety Communication reinforcing this warning across all serotonergic medications 9. Signs include agitation, hyperthermia, clonus, and diaphoresis. This scenario is common: a 55-year-old on sertraline for depression who receives low-dose trazodone for insomnia is taking two serotonergic agents.

Anticoagulants and antiplatelets. Post-marketing reports have linked trazodone use with altered prothrombin time in patients on warfarin. The mechanism is not fully established, but INR monitoring should increase in frequency during trazodone initiation for any patient on warfarin.

Antihypertensives. As discussed in the orthostatic hypotension section, additive blood pressure lowering is predictable and must be managed proactively.

Dosing Strategy for Insomnia in This Age Group

The effective hypnotic dose of trazodone is far lower than its antidepressant dose. Most sleep medicine clinicians prescribe 25 to 100 mg at bedtime for insomnia, compared with 150 to 400 mg daily for depression. For adults aged 50 to 64, the starting dose should be 25 mg.

Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Sciences at the University of California, San Francisco, has stated: "The key with trazodone for sleep is to use the lowest effective dose. Higher doses don't necessarily improve sleep architecture but do increase the side effect burden, particularly orthostatic effects and next-day sedation" 2.

Dose titration, if needed, should occur in 25 mg increments at intervals of no less than one week. The target is the lowest dose that provides consistent sleep onset within 30 minutes without next-morning grogginess. A dose of 50 mg is sufficient for most patients in this age range. If 100 mg fails to produce adequate sleep, the diagnosis should be reconsidered rather than the dose increased further.

Timing matters as well. Trazodone's peak plasma concentration occurs approximately one to two hours after oral administration. Patients should take the dose 30 to 60 minutes before their intended bedtime, with food. Taking trazodone on an empty stomach accelerates absorption and may intensify dizziness and lightheadedness during the absorption peak.

Perimenopause, Andropause, and Trazodone

The 50-to-64 window overlaps directly with perimenopause in women and the gradual testosterone decline in men. Both hormonal transitions disrupt sleep architecture. The Study of Women's Health Across the Nation (SWAN) found that 38% of women in the late menopausal transition reported frequent night awakenings, compared with 28% of premenopausal women 10.

Trazodone addresses one piece of this problem: its serotonin-2A receptor antagonism promotes slow-wave sleep and reduces nighttime awakenings. It does not, however, address vasomotor symptoms (hot flashes and night sweats), which are a primary driver of perimenopausal insomnia. The Endocrine Society's 2015 clinical practice guideline for treatment of menopausal symptoms recommends hormone therapy as first-line for vasomotor-driven sleep disruption 11. If a woman's insomnia is primarily caused by hot flashes, trazodone alone is an incomplete treatment.

For men with low testosterone and associated sleep disturbance, the picture is similarly layered. Testosterone replacement can improve subjective sleep quality in hypogonadal men, but the evidence base remains mixed. Trazodone may serve as a reasonable adjunct while testosterone levels are being optimized, but it should not substitute for addressing the underlying hormonal deficit.

The Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism notes that "sleep disturbance is a common symptom of testosterone deficiency and may improve with testosterone replacement therapy" 12.

Priapism: A Rare but Serious Risk

Trazodone's alpha-adrenergic blocking activity can cause priapism, a sustained, painful erection lasting more than four hours. This is a urologic emergency. Estimates range from 1 in 6,000 to 1 in 8,000 male patients prescribed trazodone 13. The incidence is low but the consequence is severe: untreated priapism can result in permanent erectile dysfunction.

Men aged 50 to 64 who are concurrently using phosphodiesterase-5 inhibitors (sildenafil, tadalafil) for erectile dysfunction face compounded risk. Both drug classes affect penile smooth muscle tone through different mechanisms, and concurrent use is not contraindicated, but it requires explicit counseling. Every male patient in this age group starting trazodone should receive clear verbal and written instructions: if an erection lasts longer than four hours, present to an emergency department immediately. Do not wait until morning.

How Trazodone Compares to Other Sleep Agents for This Age Group

Choosing a sleep medication for a 55-year-old with chronic insomnia requires weighing several trade-offs. Zolpidem (Ambien) is FDA-approved for insomnia but carries risks of complex sleep behaviors (sleepwalking, sleep-driving) and next-day impairment. The FDA reduced the recommended zolpidem dose for women to 5 mg in 2013 after pharmacokinetic data showed higher morning blood levels in female patients 14.

Benzodiazepines (temazepam, lorazepam) remain effective hypnotics but carry well-documented risks of tolerance, dependence, and cognitive impairment with long-term use. The American Geriatrics Society Beers Criteria, while formally targeting adults 65 and older, flags benzodiazepines as potentially inappropriate due to fall risk and cognitive effects 15. Many clinicians apply this caution to the 50-to-64 group as well, especially in patients with early cognitive concerns.

Suvorexant (Belsomra) and lemborexant (Dayvigo), the dual orexin receptor antagonists, represent a newer option with a distinct mechanism. They do not cause respiratory depression and have a lower abuse potential than Z-drugs. However, they cost significantly more than generic trazodone and are not universally covered by insurance.

Trazodone's advantages in this comparison are cost, lack of DEA scheduling, absence of respiratory depression, and promotion of slow-wave sleep. Its disadvantages are the orthostatic and cardiac effects discussed above, plus the absence of a strong RCT evidence base specifically for the insomnia indication.

Monitoring Recommendations for the First 90 Days

The first three months on trazodone are the highest-risk period for adverse events in the 50-to-64 age group. A structured monitoring plan should include:

Before starting. Obtain a baseline ECG if any cardiac risk factor is present. Review the full medication list for CYP3A4 inhibitors, serotonergic drugs, and antihypertensives. Check a metabolic panel, including potassium and magnesium, since hypokalemia and hypomagnesemia increase QT prolongation risk.

Week one. Measure standing and seated blood pressure. Ask about dizziness, lightheadedness, morning sedation, and (in men) any prolonged erections.

Week four. Reassess sleep quality using a validated tool such as the Pittsburgh Sleep Quality Index (PSQI). If trazodone has not improved sleep onset latency or maintenance by week four at 50 mg, consider alternative diagnoses (obstructive sleep apnea, restless legs syndrome) rather than dose escalation.

Month three. Repeat ECG if the dose has been increased above 50 mg or if any new QT-prolonging medication has been added. Review the continued indication: is trazodone still needed, or can it be tapered? The goal with any hypnotic should be the shortest effective duration of use.

Long-term trazodone use for insomnia is common in clinical practice, but no randomized trial has evaluated its safety or efficacy beyond 6 weeks for the insomnia indication. Periodic reassessment, at minimum every 6 months, is a reasonable standard of care.

When to Avoid Trazodone Entirely

Certain clinical scenarios make trazodone a poor choice regardless of dose. Patients with a history of QT prolongation or torsades de pointes should not receive trazodone. Patients recovering from acute myocardial infarction should avoid it during the early recovery phase per the FDA label 3. Active hepatic impairment can prolong the half-life unpredictably, raising the risk of accumulation and excessive sedation.

Patients taking strong CYP3A4 inhibitors (particularly ritonavir or cobicistat-containing HIV regimens) should either use an alternative sleep agent or have trazodone doses reduced by at least 50% with close follow-up. Patients with a history of priapism should not receive trazodone. Patients with uncontrolled orthostatic hypotension, regardless of cause, should be treated with a non-alpha-blocking alternative.

The clinical decision should always begin with the question: what is the primary cause of this patient's insomnia? If the answer is vasomotor symptoms, treat the hormonal deficit. If the answer is obstructive sleep apnea, prescribe CPAP. Trazodone is a reasonable option when the sleep complaint is primary insomnia or insomnia comorbid with depression, and when the cardiac and hemodynamic profile allows safe use.